| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8786025 | Clinical Oncology | 2018 | 7 Pages |
Abstract
With all limitations of such a rare disease and small data set, objective response and survival outcomes are similar in epithelioid sarcoma to non-selected sarcoma populations. The clinical testing of novel systemic treatments for epithelioid sarcoma remains an unmet medical need and a high priority.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
N. Touati, P. Schöffski, S. Litière, I. Judson, S. Sleijfer, W.T. van der Graaf, A. Italiano, N. Isambert, T. Gil, J.Y. Blay, D. Stark, T. Brodowicz, S. Marréaud, A. Gronchi,